Eloxx Pharmaceuticals Reports Board and Compensation Changes
Ticker: ELOX · Form: 8-K · Filed: Aug 12, 2025 · CIK: 1035354
| Field | Detail |
|---|---|
| Company | Eloxx Pharmaceuticals, Inc. (ELOX) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Eloxx Pharma shakes up board, adjusts exec pay.
AI Summary
Eloxx Pharmaceuticals, Inc. announced on August 6, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal restructuring or strategic shifts that may carry inherent risks.
Key Players & Entities
- Eloxx Pharmaceuticals, Inc. (company) — Registrant
- August 6, 2025 (date) — Date of earliest event reported
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates changes in directors and certain officers, but does not specify the exact roles vacated in this excerpt.
Who are the newly elected directors?
The filing mentions the election of directors but does not list their names in this excerpt.
What are the key changes in the compensatory arrangements?
The filing states there are updates to compensatory arrangements but does not detail the specific changes in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on August 6, 2025.
What is the SEC file number for Eloxx Pharmaceuticals?
The SEC file number for Eloxx Pharmaceuticals is 001-31326.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-08-12 17:22:54
Key Financial Figures
- $0.01 — e on which registered Common Stock, $0.01 par value per share ELOX OTC Pink Mar
Filing Documents
- tm2523236d1_8k.htm (8-K) — 25KB
- 0001104659-25-076933.txt ( ) — 183KB
- elox-20250806.xsd (EX-101.SCH) — 3KB
- elox-20250806_lab.xml (EX-101.LAB) — 33KB
- elox-20250806_pre.xml (EX-101.PRE) — 22KB
- tm2523236d1_8k_htm.xml (XML) — 3KB
02 Departure of Directors or Certain Officers; Election of Directors;
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Resignation On August 6, 2025, Ms. Lindsay Androski notified the Board of Directors (the "Board") of Eloxx Pharmaceuticals, Inc. (the "Company") of her resignation from the Board. The resignation is effective as of August 6, 2025 and did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 12, 2025 ELOXX PHARMACEUTICALS, INC. By: /s/ Sumit Aggarwal Name: Sumit Aggarwal Title: President and Chief Executive Officer